DoriVac DNA Origami Vaccines: Preclinical Immunogenicity and Translational Notes

The DoriVac DNA origami vaccine platform is a DNA nanostructure “chassis” evaluated in preclinical mouse studies and in a microfluidic human lymph node–on-a-chip model, with both settings presented as generating robust humoral and cellular immune signals. The central idea is nanoscale control over how antigens and immune-stimulating molecules are displayed on a folded DNA nanostructure to shape immune recognition.

DoriVac is built from tiny, self-assembling square DNA origami nanostructures with two functional faces: adjuvant molecules arranged on one side at controlled nanometer spacing, and selected antigens displayed on the opposite side. Antigen examples include peptides from a conserved heptad repeat 2 (HR2) region in viral spike proteins, described as relevant across viruses such as SARS-CoV-2, HIV, and Ebola. The study attributes to the investigators the view that this nanoscale “patterning” can be used to “program” immune recognition in targeted immune cells by controlling vaccine composition and presentation. In contrasting this with mRNA lipid nanoparticle (LNP) approaches, the study emphasizes that DoriVac uses a structural DNA scaffold that carries antigen and adjuvant displays rather than an mRNA-in-LNP delivery system, keeping spatial arrangement as the primary design variable.

In mice, DoriVac formulations produced stronger humoral and cellular immune responses than comparable origami-free combinations of antigens and adjuvants. The study describes increased numbers of antibody-producing B cells, activated antigen-presenting dendritic cells, and antigen-specific memory and cytotoxic T cells—cell types the authors describe as vital for long-term protection—after vaccination with the SARS-CoV-2 HR2 construct. The authors characterize these shifts as activation across multiple immune cell types in early studies.

In the human lymph node–on-a-chip system described, t a SARS-CoV-2 HR2 DoriVac vaccine activated human dendritic cells and increased their production of inflammatory cytokines compared with origami-free components, while also expanding CD4+ and CD8+ T cells reported to have multiple protective functions. The study also describes a head-to-head mouse booster comparison using a DoriVac vaccine presenting the full SARS-CoV-2 spike protein, which it says produced similar antibody and antiviral T-cell responses to Moderna and Pfizer/BioNTech mRNA-LNP boosters encoding the same spike protein. The authors convey that DNA origami vaccines may offer logistical advantages—described in terms of improved stability and easier storage, manufacture, and distribution relative to mRNA-LNP vaccines—and note that related DoriNano studies are said to show a promising safety profile.